ALX Oncology Holdings Inc.

NASDAQ:ALXO

Biotechnology

Healthcare
$0.97 -2.12%

-$0.03 today

Market cap
$134.14M
Beta
0.45
P/E (TTM)
-0.9
EPS (TTM)
-$1.64
52W Low $0.40High $2.66

Volume 0.56M

Average 1.07M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$104.02M

FY 2025 · Annual

Net Income

-$101.69M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development60.17M98.4M141.8M116.37M77M
Selling, General & Admin23.39M29.04M28.48M26.09M23.85M
Operating Expenses83.56M127.44M170.28M142.47M104.02M
Depreciation & Amortization51K342K836K872K706K
EBITDA(83.42M)(122.84M)(158.4M)(132.25M)(99.39M)
EBITDA Margin—————
Operating Income(83.56M)(127.44M)(170.28M)(142.47M)(104.02M)
Operating Margin—————
Interest Income914.28M10.65M9.37M3.96M
Interest Expense13K238K1.57M1.73M1.6M
Other Income / Expenses71K4.02M9.47M7.62M2.33M
Income Before Tax(83.48M)(123.42M)(160.81M)(134.85M)(101.7M)
Pre-Tax Margin—————
Income Tax Expense(21K)64K000
Net Income(83.46M)(123.48M)(160.81M)(134.85M)(101.7M)
Net Margin—————
EPS (Basic)(2.07)(3.03)(3.74)(2.58)(1.90)
EPS (Diluted)(2.07)(3.03)(3.74)(2.58)(1.90)
Weighted Avg Shares40.31M40.7M42.99M52.17M53.66M
Weighted Avg Shares (Diluted)40.31M40.7M42.99M52.17M53.66M

ALXO Earnings Waterfall · TTM

NASDAQ:ALXO · Revenue to Net Income

Key Ratios

EPS$-1.65
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-0.9
P/S Ratio0.0

Analysis

$0 of revenue converted into -$88.9M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.65, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13D/ASC 13D/A filingOct 16, 2026
8-KCurrent reportOct 15, 2026
4Statement of changes in beneficial ownershipAug 18, 2026
4Statement of changes in beneficial ownershipAug 18, 2026
SC 13G/ASC 13G/A filingAug 14, 2026

How much revenue does ALXO generate?

ALX Oncology Holdings Inc. (ALXO) reported $0.00 of revenue in fiscal 2025.

Is ALXO profitable?

ALX Oncology Holdings Inc. (ALXO) reported -$101.69M of net income.